Amgen: Clinical Trials

376 trials sponsored by Amgen, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

276 completed, 34 terminated, 30 active not recruiting, 28 recruiting. 376 Phase 3, 14 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	376	Completed 276, Terminated 34, Active not recruiting 30, Recruiting 28, Withdrawn 4, Not yet recruiting 3, Unknown 1
Phase 2	14	Completed 8, Terminated 4, Active not recruiting 1, Recruiting 1

Follow Amgen: new trials by email

Trials (filtered) newest first · largest first

All 376 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia	Phase 3	Not yet recruiting	Amgen	560	2028-06-30	2026-09-15
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer	Phase 3	Not yet recruiting	PrECOG, LLC.	430	2027-01-01	2026-06-09
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH	Phase 3	Recruiting	Amgen	180	2026-12-18	2026-11-03
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight Maridebart cafraglutide, Autoinjector - Obesity, Overweight	Phase 3	Not yet recruiting	Amgen	230	2026-10-28	2026-10-13
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Maridebart cafraglutide, Semaglutide - Diabetes Mellitus, Type 2	Phase 3	Recruiting	Amgen	1300	2026-10-16	2026-11-05
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous	Phase 3	Recruiting	Amgen	159	2026-10-01	2026-10-01
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Tarlatamab - Small Cell Lung Cancer	Phase 3	Recruiting	Amgen	400	2026-08-28	2026-09-17
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia	Phase 3	Recruiting	Amgen	126	2026-08-21	2026-09-17
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Maridebart Cafraglutide, Placebo - Obesity, Overweight	Phase 3	Recruiting	Amgen	950	2026-07-29	2026-10-05
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) Maridebart cafraglutide, Placebo - Obesity, Overweight	Phase 3	Recruiting	Amgen	3200	2026-07-23	2026-10-05
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration ABP 938 8 mg, Aflibercept (US) 8 mg - Neovascular Age-related Macular Degeneration, nAMD	Phase 3	Recruiting	Amgen	304	2026-05-27	2026-10-14
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's	Phase 2 / Phase 3	Recruiting	Robert Spiera, MD	30	2026-05-22	2026-09-02
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) Maridebart Cafraglutide - Obesity or Overweight	Phase 3	Recruiting	Amgen	300	2026-05-11	2026-11-06
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial Olpasiran, Placebo - Cardiovascular Disease	Phase 3	Recruiting	Amgen	406	2026-03-23	2026-04-16
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Vitamin D, Calcium - Osteogenesis Imperfecta	Phase 3	Recruiting	Amgen	71	2026-03-18	2026-06-22
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout Pegloticase, Methotrexate - Uncontrolled Gout	Phase 3	Recruiting	Amgen	270	2026-02-09	2026-10-19
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy Maridebart cafraglutide, Placebo - Obesity, Obstructive Sleep Apnea	Phase 3	Active not recruiting	Amgen	250	2025-12-19	2026-10-06
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer	Phase 3	Recruiting	Amgen	750	2025-11-28	2026-10-20
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Maridebart cafraglutide, Placebo - Obstructive Sleep Apnea	Phase 3	Active not recruiting	Amgen	250	2025-11-25	2026-09-29
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events Olpasiran, Placebo - Cardiovascular Disease	Phase 3	Recruiting	Amgen	11000	2025-08-22	2026-08-21

Amgen: Clinical Trials

376 trials sponsored by Amgen, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials (filtered) newest first · largest first

Conditions studied

Interventions

Countries

Top investigators

Results publications

NIH funding